Merck Earnings Preview: Keytruda's Medicare Exposure Is the Key Line
As seen on the 24/7 Wall St. homepage on August 4, 2026.
Merck reports before the open at 6:30 AM ET, and the line that matters is Keytruda: any guidance language on Medicare price negotiation exposure sets the tone for oncology peers like Pfizer and Bristol Myers Squibb. Confirmed date, so no surprises on timing.
Continue ReadingShow less
Merck releases its results before the open on August 4, with the report dropping at 6:30 AM ET. The timing is confirmed, so investors know exactly when to watch, but the bigger question is what management says rather than when they say it.
All eyes will be on Keytruda, Merck's flagship cancer therapy. Any guidance language around Medicare drug price negotiation exposure will carry weight well beyond Merck itself — oncology peers like Pfizer and Bristol Myers Squibb are watching closely, since the tone Merck sets could signal how the broader sector frames its own negotiation risk going forward.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
Because the date and time are locked in with no ambiguity, the pre-market window before trading opens will be the critical period for investors to absorb both the headline numbers and, more importantly, whatever Merck's management says about Keytruda's pricing outlook.
Sources
Mentioned: MRK